Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: an experimental study

References

• 1. Page last reviewed: april 2, 2013 Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP) (April 2, 2013). https://www.cdc.gov/hai/organisms/pseudomonas.html
  Google Scholar
• 2. Gupta M, Kumar A. Comparison of minimum inhibitory concentration (MIC) value of statin drugs: a systematic review. Anti-Infect. Agents 17(1), 4–19 (2019).
  CASGoogle Scholar
• 3. Rana R, Sharma R, Kumar A. Repurposing of existing statin drugs for treatment of microbial infections: how much promising? Infect. Disord. Drug Targets 19(3), 224–237 (2018).
  Google Scholar
• 4. Sethi K, Singh A, Kumar A. Exploring the therapeutic potential of atorvastatin against Gram-positive and Gram-negative bacteria: in silico, in vitro and in vivo evidence. Infect. Disord. Drug Targets 20(6), 798–815 (2020).
  Medline CASGoogle Scholar
• 5. Kapoor Y, Sharma R, Kumar A. Repurposing of existing drugs for the bacterial infections: an in silico and in vitro study. Infect. Disord. Drug Targets 20(2), 182–197 (2020).
  Medline CASGoogle Scholar
• 6. Gupta M, Sharma R, Kumar A. Comparative potential of simvastatin, rosuvastatin and fluvastatin against bacterial infection: an in silico and in vitro study. Orient. Pharm. Exp. Med. 19(3), 259–275 (2019).
  CASGoogle Scholar
• 7. Rana R, Sharma R, Kumar A. Repurposing of Fluvastatin against Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy: an in silico and in vitro study. Curr. Mol. Med. 19(7), 506–524 (2019).
  Medline CASGoogle Scholar
• 8. Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med. Chem. 9(5), 481–499 (2009).
  Medline CASGoogle Scholar
• 9. Haskell SG. Selective estrogen receptor modulators (featured CME topic). South Med. J. 96(5), 469–477 (2003).
  MedlineGoogle Scholar
• 10. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med. Res. Rev. 21(4), 302–347 (2001).
  Medline CASGoogle Scholar
• 11. Eder SE. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia. Women Health 10(5), 499–503 (2014).
  CASGoogle Scholar
• 12. Gennari L, Merlotti D, Nuti R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin. Inter. Aging. 5, 19–29 (2010).
  Medline CASGoogle Scholar
• 13. Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116(3), 561–570 (2006).
  Medline CASGoogle Scholar
• 14. Xu B, Lovre D, Mauvais-Jarvis F. The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: basic and clinical insights. J. Diabetes Complications 31(4), 773–779 (2017).
  MedlineGoogle Scholar
• 15. Barreto GE, Santos-Galindo M, Garcia-Segura LM. Selective estrogen receptor modulators regulate reactive microglia after penetrating brain injury. Front. Aging Neurosci. 6, 132 (2014).
  MedlineGoogle Scholar
• 16. Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular effects of selective estrogen receptor modulators. Ann. NY Acad. Sci. 1092(1), 374–384 (2006).
  Medline CASGoogle Scholar
• 17. Hussein MH, Schneider EK, Elliott AG et al. From breast cancer to antimicrobial: combating extremely resistant Gram-negative “superbugs” using novel combinations of polymyxin B with selective estrogen receptor modulators. Microb. Drug Resist. 23(5), 640–650 (2017).
  Medline CASGoogle Scholar
• 18. Sui SJ, Lo R, Fernandes AR et al. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int. J. Antimicrob. Agents 40(3), 246–251 (2012).
  MedlineGoogle Scholar
• 19. Wiseman H, Cannon M, Arnstein HR. Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the antioestrogen drug tamoxifen. Biochem. Soc. Trans. 17, 1038–1039 (1989).
  Medline CASGoogle Scholar
• 20. Doroodgar M, Delavari M, Doroodgar M, Abbasi A, Taherian AA, Doroodgar A. Tamoxifen induces apoptosis of Leishmania major promastigotes in vitro. Korean J. Parasitol. 54(1), 9–14 (2016).
  Medline CASGoogle Scholar
• 21. Reimão JQ, Miguel DC, Taniwaki NN, Trinconi CT, Yokoyama-Yasunaka JK, Uliana SR. Antileishmanial activity of the estrogen receptor modulator raloxifene. PLoS Negl. Trop. Dis. 8(5), e2842 (2014).
  MedlineGoogle Scholar
• 22. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA, Uliana SR. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J. Antimicrob. Chemother. 60(3), 526–534 (2007).
  Medline CASGoogle Scholar
• 23. Trinconi CT, Reimão JQ, Coelho AC, Uliana SR. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J. Antimicrob. Chemother. 71(5), 1314–1322 (2016).
  MedlineGoogle Scholar
• 24. Dittmar AJ, Drozda AA, Blader IJ. Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth. mSphere 1(2), e00042-15 (2016).
  MedlineGoogle Scholar
• 25. Escobedo G, Palacios-Arreola MI, Olivos A, López-Griego L, Morales-Montor J. Tamoxifen treatment in hamsters induces protection during taeniosis by Taenia solium. Bio. Med. Res. Int. 2013, 280496 (2013).
  MedlineGoogle Scholar
• 26. Cong Y, Hart BJ, Gross R et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS ONE 13(3), e0194868 (2018).
  MedlineGoogle Scholar
• 27. Sun W, He S, Martínez-Romero C et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res. 137, 165–172 (2017).
  Medline CASGoogle Scholar
• 28. Zhao Y, Ren J, Harlos K et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535(7610), 169–172 (2016).
  Medline CASGoogle Scholar
• 29. Butts A, Koselny K, Chabrier-Roselló Y et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. MBio 5(1), e00765-13 (2014).
  MedlineGoogle Scholar
• 30. Jang WS, Kim S, Podder B et al. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J. Microbiol. Biotechnol. 25(6), 946–950 (2015).
  Medline CASGoogle Scholar
• 31. Theophel K, Schacht VJ, Schlüter M et al. The importance of growth kinetic analysis in determining bacterial susceptibility against antibiotics and silver nanoparticles. Front. Microbiol. 5, 544 (2014).
  MedlineGoogle Scholar
• 32. Graziano TS, Cuzzullin MC, Franco GC et al. Statins and antimicrobial effects: simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS ONE 10(5), e0128098 (2015).
  MedlineGoogle Scholar
• 33. Yang B, Lei Z, Zhao Y et al. Combination susceptibility testing of common antimicrobials in vitro and the effects of sub-MIC of antimicrobials on Staphylococcus aureus biofilm formation. Front. Microb. 8, 2125 (2017).
  MedlineGoogle Scholar
• 34. Neely MN, Pfeifer JD, Caparon M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect. Immun. 70(7), 3904–3914 (2002).
  Medline CASGoogle Scholar
• 35. Sundaramoorthy NS, Mohan HM, Subramaniam S et al. Ursolic acid inhibits colistin efflux and curtails colistin resistant Enterobacteriaceae. AMB Express 9(1), 27 (2019).
  MedlineGoogle Scholar
• 36. Farha MA, Czarny TL, Myers CL et al. Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. Proc. Natl Acad Sci. USA 112(35), 11048–11053 (2015).
  Medline CASGoogle Scholar
• 37. Jacobs AC, DiDone L, Jobson J, Sofia MK, Krysan D, Dunman PM. Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents. Antimicrob. Agents Chemother. 57(1), 26–36 (2013).
  Medline CASGoogle Scholar
• 38. Dufour D, Leung V, Lévesque CM. Bacterial biofilm: structure, function, and antimicrobial resistance. Endod. Topics 22(1), 2–16 (2010).
  Google Scholar
• 39. Algburi A, Comito N, Kashtanov D, Dicks LM, Chikindas ML. Control of biofilm formation: antibiotics and beyond. Appl. Environ. Microbiol. 83(3), e02508-16 (2017).
  MedlineGoogle Scholar
• 40. Yasir M, Willcox M, Dutta D. Action of antimicrobial peptides against bacterial biofilms. Materials 11(12), e2468 (2018).
  MedlineGoogle Scholar
• 41. Torres NS, Montelongo-Jauregui D, Abercrombie JJ et al. Antimicrobial and antibiofilm activity of synergistic combinations of a commercially available small compound library with colistin against Pseudomonas aeruginosa. Front. Microbiol. 9, 2541 (2018).
  MedlineGoogle Scholar
• 42. Cheesman MJ, Ilanko A, Blonk B, Cock IE. Developing new antimicrobial therapies: are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution? Pharmacogn. Rev. 11(22), 57–72 (2017).
  Medline CASGoogle Scholar
• 43. Delattin N, De Brucker K, Vandamme K et al. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J. Antimicrob. Chemother. 69(4), 1035–1044 (2013).
  MedlineGoogle Scholar
• 44. Trinconi CT, Reimão JQ, Yokoyama-Yasunaka JK, Miguel DC, Uliana SR. Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 58(5), 2608–2613 (2014).
  MedlineGoogle Scholar
• 45. Sullivan C, Matty MA, Jurczyszak D et al. Infectious disease models in zebrafish. Methods Cell Biol. 138, 101–136 (2017).
  Medline CASGoogle Scholar
• 46. Gupta M, Sharma R, Singh M, Kumar A. Docking techniques in pharmacology: how much promising? Comput. Biol. Chem. 76, 210–217 (2018).
  Medline CASGoogle Scholar
• 47. Garg A, Singh B, Sharma R, Singh A, Kumar A. Selective estrogen receptor modulators (SERMs): mechanistic insights against microbial infections. Curr. Mol. Med. 20(2), 102–115 (2019).
  Google Scholar
• 48. Oefner C, Bandera M, Haldimann A et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J. Antimicrob. Chemother. 63(4), 687–698 (2009).
  Medline CASGoogle Scholar
• 49. Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb. Perspect. Med. 6(8), a025247 (2016).
  MedlineGoogle Scholar